Right drug, wrong delivery. I suspect it will show excellent preclinical data. Pretty skeptical is a bit of an understatement? Has zero chance as an eyedrop.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.